Gasparini M, Bombardieri E, Tondini C, Maffioli L, Hughes L, Burraggi G L, Goldenberg D M
Nuclear Medicine Department, National Cancer Institute, Milan, Italy.
Tumori. 1995 May-Jun;81(3):173-8. doi: 10.1177/030089169508100304.
Adequate clinical staging of non-Hodgkin's lymphoma patients is essential because only localized disease can be treated satisfactorily. Many imaging procedures are necessary to stage the disease accurately. The objective of this study was to evaluate the efficacy of an antilymphoma antibody in the Fab' fragment form, labelled with 99mTc, to detect malignant lesions.
Radioimmunodetection (RAID) with 99mTc-labelled B-cell lymphoma monoclonal antibody IMMU-LL2-Fab' (LymphoSCAN; Immunomedics, Morris Plain, NJ, USA) was investigated in 10 patients (5 females and 5 males; age range, 20-72 years) with histologically proved non-Hodgkin's lymphoma. Of the 10 lymphomas, 7 were intermediate grade and 3 were low grade. Whole body images with multiple planar views were obtained at 30 min, 4-6 and 24 h after i.v. injection of 1 mg LL2-Fab' labelled with 740-925 MBq of 99mTc. SPET of the chest or abdomen was performed in all patients 5-8 h after the immunoreagent injection.
No adverse reactions were observed in any patient after Mab infusion, and no appreciable changes were seen in the blood counts, renal or liver function tests. A total of 18 of 21 (85.7%) lymphoma lesions were detected by RAID. All the tumor localizations were confirmed by clinical examination and with other imaging techniques, such as CT scan, MRI or gallium scan. In this series of patients no false-positive results were noted. As regards the biodistribution of the immunoreagent, no appreciable bone marrow activity was seen; splenic targeting was demonstrated in all patients; the tumor-to-non-tumor ratios ranged from 1.2 to 2.8 ad measured by the ROI technique; no difference in uptake was noted for different tumor grades. The images obtained 24 h after injection did not reveal new lesions, but areas of doubtful uptake were seen as positive focal areas in the delayed scan.
LymphoSCAN seems to be useful for detection, staging and follow-up of non-Hodgkin's lymphoma patients.
对非霍奇金淋巴瘤患者进行充分的临床分期至关重要，因为只有局限性疾病才能得到满意的治疗。准确分期该疾病需要多种影像学检查。本研究的目的是评估以99mTc标记的Fab'片段形式的抗淋巴瘤抗体检测恶性病变的疗效。
对10例经组织学证实为非霍奇金淋巴瘤的患者（5例女性和5例男性；年龄范围20 - 72岁）进行了用99mTc标记的B细胞淋巴瘤单克隆抗体IMMU - LL2 - Fab'（LymphoSCAN；Immunomedics，美国新泽西州莫里斯平原）的放射免疫检测（RAID）。在这10例淋巴瘤中，7例为中级，3例为低级。静脉注射1mg用740 - 925MBq的99mTc标记的LL2 - Fab'后30分钟、4 - 6小时和24小时获得多个平面视图的全身图像。在注射免疫试剂后5 - 8小时对所有患者进行胸部或腹部单光子发射计算机断层扫描（SPET）。
在输注单克隆抗体后，所有患者均未观察到不良反应，血常规、肾功能或肝功能检查也未见明显变化。通过RAID共检测到21个淋巴瘤病变中的18个（85.7%）。所有肿瘤定位均通过临床检查以及其他成像技术如CT扫描、MRI或镓扫描得以证实。在这组患者中未发现假阳性结果。关于免疫试剂的生物分布，未观察到明显的骨髓活性；所有患者均显示脾脏摄取；通过感兴趣区（ROI）技术测量，肿瘤与非肿瘤的比值范围为1.2至2.8；不同肿瘤分级在摄取方面未观察到差异。注射后24小时获得的图像未显示新病变，但在延迟扫描中，摄取可疑区域被视为阳性局灶区。
LymphoSCAN似乎对非霍奇金淋巴瘤患者的检测、分期和随访有用。
